JAK Inhibitor Efficacy & Safety
A Closer Look at RA Treatment: JAK Inhibitor Efficacy and Safety

Released: December 11, 2020

Expiration: December 10, 2021

Stanley B. Cohen
Stanley B. Cohen, MD
Sheetal Desai
Sheetal Desai, MD, MSEd
Eric M. Ruderman
Eric M. Ruderman, MD

Activity

Progress
1
Course Completed

In this episode, Dr. Stanley Cohen, Dr. Sheetal Desai, and Dr. Eric Ruderman interpret the latest safety and efficacy data for JAK inhibitors in RA, including the ORAL, BEACON, BEAM, SELECT, and FINCH series in

  • bDMARD-IR
  • MTX-IR
  • MTX naive

Also included is an in-depth discussion of JAK safety, including MACE and VTE, and use in the clinic including JAK cycling

Presenters:

Stanley B. Cohen, MD
Clinical Professor
Department of Internal Medicine
University of Texas Southwestern Medical School
Co-Director
Division of Rheumatology
Presbyterian Hospital
Co-Medical Director
Metroplex Clinical Research Center
Dallas, Texas  

Sheetal Desai, MD, MSEd
Chief of Rheumatology
Program Director
University of California, Irvine
Irvine, California

Eric M. Ruderman, MD
Professor, Associate Chief
Division of Rheumatology
Northwestern University Feinberg School of Medicine
Clinical Practice Director
Northwestern Medical Group
Chicago, Illinois